Deals and Financings

• Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer degrader drug from Boston’s C4 Therapeutics in a deal worth up to $392 million;
• Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for two synthetic lethality PARP inhibitors to Eikon Therapeutics, a San Francisco biopharma with $600 million in venture capital;
• Lynk Pharma of Hangzhou raised $28 million in a Series C1 financing to advance its first-in-class and best-in-class small molecule candidates for oncology and autoimmune diseases;
• invoX Pharma, a UK subsidiary of Sino Biopharm, completed a second investment tranche in pHion Therapeutics, a Belfast company developing mRNA vaccines for oncology and infectious diseases;

Trials and Approvals

• Beijing CANbridge Pharma was approved to launch Maralixibat Chloride Oral Solution (Livmarli®) in China to treat cholestatic pruritus in patients with Alagille syndrome;
• Connect Biopharma, a Foster City-Taicang company developing inflammation drugs, announced that its S1P1 modulator showed statistically significant improvement in ulcerative colitis patients;
• Shanghai Unicar-Therapy said its CD19/CD22 dual-target CAR T-cell therapies outperformed single CD19 CAR-T candidates in patients with B-cell acute lymphoblastic leukemia;
• HighField Biopharma, a Hangzhou company, published positive early data from a Phase Ia trial of its lead immunoliposomes drug in metastatic cancer patients.
  
  Share this with colleagues:  
  
  

Beijing CANbridge Pharma was approved to launch Maralixibat Chloride Oral Solution (Livmarli®) in China to treat cholestatic pruritus in patients at least one year old with Alagille syndrome. Livmarli (maralixibat) inhibits ileal bile acid transporters (IBAT), blocking bile circulation and lowering bile acid levels in the liver and serum. This reduces liver injury and relieves pruritus. Livmarli is the only medication approved in China, the US and EU to treat Alagille syndrome cholestatic pruritus. CANbridge, a rare disease company, acquired China rights for Livmarli from Mirum Pharma, a San Francisco-area biopharma. More details....

Stock Symbol: (HK: 1228)

Share this with colleagues:  

Connect Biopharma, a Foster City-Taicang company developing therapies for inflammation, announced that its S1P1 modulator showed statistically significant improvement in patients with ulcerative colitis (UC) during a Phase II trial. The study evaluated icanbelimod (CN002) over a 36-week maintenance period following a 12-week induction period. In the four-country Phase II trial, CN002, an oral selective sphingosine 1-phosphate receptor 1 (S1P1) modulator, was administered once daily. Connect Bio believes that icanbelimod could be a best-in-class S1P1 modulator. More details....

Stock Symbol: (NSDQ: CNTB)

Share this with colleagues:  

Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for two PARP inhibitors to Eikon Therapeutics, a San Francisco biopharma that has raised $600 million to develop novel oncology drugs. Impact is building a portfolio of cancer drugs based on the concept of synthetic lethality, which aims to take advantage of cancer cells’ genomic instability. Eikon will have rights to IMP1734, a selective PARP inhibitor of cancer cells that is expected to start clinical trials in 2H23, and another PARP inhibitor, probably IMP4297, currently in Phase II/III trials for ovarian and other solid tumor cancers. Financial details were not disclosed. More details....

Share this with colleagues:  

invoX Pharma, a UK subsidiary of Sino Biopharm (HK: 1177), completed a second investment tranche in pHion Therapeutics, a Belfast company developing mRNA vaccines for oncology and infectious diseases. pHion’s proprietary platform is designed to deliver anionic mRNA and saRNA molecules that evade detection and generate an antigen-specific CD8+ T-cell response. invoX positioned the investment as part of its strategy to be a fully integrated biopharma. One year ago, invoX paid $161 million to acquire another novel UK company, F-Star, a Cambridge, UK clinical stage company that develops bispecific drugs for immunotherapies. More details....

Share this with colleagues: